StockpollyBeta
Get App
Popularity #2,122
ACRS · NASDAQ · Biotechnology

Aclaris Therapeutics (ACRS)

Develops immunology drug candidates through biologics, kinase inhibitors, and discovery services.

$5.15
vs last close−0.58 (−10.05%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue9182349123122
Cost of revenue862229121−100
Gross profit1111120103221
3315191412100191820252426
Research & development242710969121113171619
787565655676
Selling & marketing000000000000
General & administrative787565655676
Other expenses2−2030186122311
Operating income−32−4−19−13−10−100−18−18−17−23−22−24
222233333323
Interest income202222222222
Other non-operating income−220−30−1−860−2−3−3−2−3
Income before tax−29−2−17−11−8−97−15−15−15−20−20−22
Income tax expense000000000000
Net income from continuing operations−29−1−17−11−8−97−15−15−15−20−20−22
Net income−29−1−17−11−8−97−15−15−15−20−20−22
EPS, basic−$0.41−$0.02−$0.24−$0.15−$0.11−$1.01−$0.12−$0.13−$0.12−$0.16−$0.15−$0.15
EPS, diluted−$0.41−$0.02−$0.24−$0.15−$0.11−$1.01−$0.12−$0.13−$0.12−$0.16−$0.15−$0.15
Weighted average shares, basic717171717195122123123123129143
Weighted average shares, diluted717171717195122123123123129143
EBITDA−29−24−16−13−9−14−18−17−14−20−20−21
Depreciation & amortization000000000000
EBIT−30−24−16−13−10−14−18−17−15−20−20−22